Paging Dr. AI; Myth Busting in Cancer; Oncologists Shine in Malpractice Survey

Could the growing influence of artificial intelligence (AI) in healthcare lead to a license to practice oncology? (ASCO AI in Oncology)

Informed by an analysis of 2,000 abdominal CT scans, a next-generation AI system helped clinicians identify pancreatic cancer up to 3 years before clinical diagnosis. (Mayo Clinic)

Using serial facial photos of patients with cancer, an AI program showed that signs of accelerated biological aging predicted lower odds for survival. (Mass General Brigham)

A phase III trial of light-activated synthetic hypericin for cutaneous T-cell lymphoma ended early after an interim analysis showed the trial was unlikely to meet the primary endpoint, Soligenix announced.

Busted: The truth behind seven myths about lung cancer. (CNN)

Sara Gore, the 49-year-old host of NBC New York’s “Open House” and “New York Live,” announced her breast cancer diagnosis. (People)

Myths, taboos, and outdated information are addressed in new prostate cancer screening guidelines for patients that also show the benefits of screening outweigh the harms, according to the National Comprehensive Cancer Network.

An overlooked measure in the 2022 Inflation Reduction Act may be helping Medicare beneficiaries with adherence to costly medications, including cancer drugs. (Undark)

While soaring prices for gasoline, food, and other household staples hog much of the affordability news, two-thirds of Americans still worry about healthcare costs, according to a KFF poll.

Despite early-stage wins, Pfizer ended development for its investigational PD-L1 inhibitor PF-08046037, citing “strategic business reasons.” (BioSpace)

During a visit to Washington, D.C., this week, members of the American Society for Radiation Oncology warned legislators that recent changes to Medicare’s radiation treatment codes could force many community clinics to close because of double-digit declines in reimbursement.

A new study from the Community Oncology Alliance showed that patients with metastatic breast cancer and non-small cell lung cancer outlived national benchmarks for survival when treated at community cancer centers.

Cancer specialists had the lowest rate of malpractice lawsuits among all specialties included in an American Medical Association survey.

The FDA called out Bayer for false and/or misleading claims about the prostate cancer drug darolutamide (Nubeqa) in consumer-directed advertising. (Fierce Pharma)

A confirmatory trial of the KRAS inhibitor adagrasib (Krazati) for advanced colorectal cancer failed to meet the primary endpoint, potentially placing the drug’s accelerated approval at risk. (ApexOnco)

Prehabilitation — exercise, nutrition, and other support before surgery — significantly reduced postoperative complications and length of hospital stay, according an analysis of 23 published studies. (Journal of the American College of Surgeons)

Please enable JavaScript to view the comments powered by Disqus.